SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJudges Scientific Regulatory News (JDG)

Share Price Information for Judges Scientific (JDG)

Share Price is delayed by 15 minutes
Get Live Data
4,450.00    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 180.00 (4.091%)
Market Cap: £296.40m
JDG Live PriceLast checked at - London Stock Exchange

Intraday Judges Scientific Share Chart

Trading Statement

18 Jul 2013 07:00

RNS Number : 5740J
Judges Scientific PLC
18 July 2013
 

 

 

Judges Scientific plc

Trading Statement

 

18 July 2013

 

Judges Scientific plc ('Judges Scientific', the 'Company' or the 'Group')

 

Trading Update

 

The Directors of Judges Scientific, the parent company of a group specialising in the design, manufacture and sale of scientific instruments, are pleased to update shareholders and the market with regard to the Group's trading performance during the first half of the current financial year.

The interim Income Statement for the six months to 30 June 2013 will not include any results from Scientifica Ltd ("Scientifica"), which was acquired on 26 June 2013 and represents the Group's largest acquisition to date. The interim Balance Sheet will reflect the acquisition.

The Group's businesses delivered a satisfactory trading performance during the period. The interim results, scheduled to be announced in September, are expected to show revenue growth of 14% compared with the six months to 30 June 2012; this includes organic growth of 4.4% and the effect of a full six-month contribution from Global Digital Systems ("GDS") and KE Developments ("KED") compared with a four-month contribution in the first half of 2012. The Board anticipates that interim profits before exceptional items will reflect this satisfactory sales performance. Adjusted basic earnings per share are also expected to advance, despite the 20% dilution resulting from the May 2012 share issue and the conversion of most of the convertible redeemable shares in the second half of 2012.

Order intake during the six-month period showed only slight organic growth, with a strong first quarter being followed by a weak second quarter. Had GDS and Scientifica been part of Judges throughout the first-half periods of both 2012 and 2013, the Group as presently constituted would have shown 13% growth in order intake for the period. The order book at 30 June 2013 (excluding Scientifica) represented 10.6 weeks of sales, somewhat ahead of the 10-week level at 30 June 2012.

Operating cash flow was healthy during the period. The interim Balance Sheet will show the impact of the Scientifica acquisition and of the majority of the building cost of the Stonecross property; net debt still rests at a prudent multiple of operating profit.

Several other companies in our sector have recently reported challenging conditions and our own markets have not been uniformly positive. However, the resilience of Judges' diversified business activities has enabled the Company to continue to pursue its objectives in a lacklustre environment.

 

 

For further information please contact:

Judges Scientific Plc

David Cicurel, CEO

Tel: 01342 323 600

 

Shore Capital (Nominated Adviser & Broker)

Pascal Keane

Edward Mansfield

Tel: 020 7408 4090

 

Cardew Group (Financial Public Relations)

Melvyn Marckus

Tel: 020 7930 0777 or 07775 896 491

 

Websites:

Judges Scientific: www.judges.uk.com 

Scientifica: http: www.scientifica.uk.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTDMGMNVNNGFZM
Date   Source Headline
4th Dec 20197:00 amRNSAcquisition of Moorfield Nanotechnology Limited
21st Nov 20197:00 amRNSSpecial dividend
15th Nov 20197:00 amRNSBlocklisting Return
7th Nov 20193:19 pmRNSDirector/PDMR Shareholding
7th Nov 20192:38 pmRNSDirector/PDMR Shareholding
1st Nov 201910:49 amRNSTotal Voting Rights
9th Oct 201910:20 amRNSDirector/PDMR Shareholding
23rd Sep 20193:49 pmRNSHolding(s) in Company
23rd Sep 20198:45 amRNSHolding(s) in Company
18th Sep 20197:00 amRNSInterim Results
16th Sep 20191:39 pmRNSHolding(s) in Company
9th Sep 201911:26 amRNSDirector/PDMR Shareholding
27th Aug 20191:18 pmRNSHolding(s) in Company
7th Aug 201910:39 amRNSDirector/PDMR Shareholding
2nd Aug 20194:01 pmRNSHolding(s) in Company
22nd Jul 20197:00 amRNSAppointment of Liberum as Joint Broker
22nd Jul 20197:00 amRNSTrading Update and Notice of Interim Results
17th Jul 201911:43 amRNSHolding(s) in Company
17th Jul 201911:41 amRNSHolding(s) in Company
12th Jul 20199:23 amRNSDirector/PDMR Shareholding
9th Jul 20195:17 pmRNSDirector/PDMR Shareholding
28th Jun 20194:27 pmRNSHolding(s) in Company
7th Jun 20199:14 amRNSDirector/PDMR Shareholding
5th Jun 201912:05 pmRNSBlock listing Interim Review
3rd Jun 201911:57 amRNSTotal Voting Rights
22nd May 20191:39 pmRNSResult of AGM
16th May 20195:37 pmRNSDirector/PDMR Shareholding
9th May 20194:14 pmRNSDirector/PDMR Shareholding
1st May 20197:00 amRNSTotal Voting Rights
29th Apr 20194:21 pmRNSNotice of AGM
9th Apr 20197:00 amRNSHolding(s) in Company
8th Apr 20195:53 pmRNSDirector/PDMR Shareholding
5th Apr 20199:30 amRNSDirector/PDMR Shareholding
1st Apr 20195:59 pmRNSHolding(s) in Company
1st Apr 201912:35 pmRNSTotal Voting Rights
22nd Mar 201911:54 amRNSHolding(s) in Company
19th Mar 20197:00 amRNSFinal Results
7th Mar 20192:22 pmRNSDirector/PDMR Shareholding
28th Feb 20197:00 amRNSTotal Voting Rights
7th Feb 20192:34 pmRNSDirector/PDMR Shareholding
5th Feb 20197:00 amRNSHolding(s) in Company
17th Jan 20197:00 amRNSTrading Statement and Notice of Final Results
9th Jan 20197:00 amRNSDirector/PDMR Shareholding
21st Dec 20183:21 pmRNSDirector/PDMR Shareholding
7th Dec 20187:00 amRNSDirector/PDMR Shareholding
4th Dec 201812:41 pmRNSHolding(s) in Company
30th Nov 20187:00 amRNSTotal Voting Rights
21st Nov 20187:00 amRNSTrading Update
15th Nov 20187:00 amRNSBlock listing Interim Review
13th Nov 20185:49 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.